차바이오텍

085660KOSDAQ기초 의약물질 제조업

49.4 / 100

Reference Date: 2026-07-24

Financial Score14.0 / 40

News Sentiment19.4 / 25

Momentum4.0 / 20

Disclosure12.0 / 15

AI Analysis: PBR is undervalued vs. peers but the high debt ratio poses financial risk. Plunged 21.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Cha BioTech primarily operates in umbilical cord blood storage, stem cell research, cell therapy development, anti-aging services, and consulting. The company also engages in pharmaceuticals, global CDMO, and international healthcare network expansion through its major subsidiaries. In 2024, revenue was distributed as 61.06% in medical services, 10.43% in product sales, and 28.51% in other services.

Number of Employees

354people

Average Salary

51.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 25.444.0Point

PBR

1.03Industry Average 1.264.0Point

In line with industry avg

ROE

-19.32Industry Average -6.033.5Point

3.2x industry avg (excellent)

Debt Ratio

51.30Industry Average 6.620.0Point

7.7x industry avg (risky)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲15.5% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼252.8% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -7.4% (declining, 3yr)

Detailed News Sentiment

9 totalPositive 8Neutral 1Negative 0Average Sentiment Score 77.8

Positive
무릎 골관절염 등 4개질환 '재생의료' 촉진…·메디포스트·차바이오...
정부의 첨단재생의료 규제 완화로 차바이오텍을 포함한 관련 기업들의 성장 기대감이 높아짐.
Positive
[클리니컬 히스토리] 마티카, 백스돔 백신 CMC로 실적검증 시험대
차바이오텍의 자회사 마티카바이오테크놀로지가 백스돔의 백신 CMC 제조를 담당함으로써 기술 협력이 강화되어 긍정적인 시장 반응을 기대할 수 있다.
Positive
마티카 바이오, 美 백스돔과 항바이러스 하이브리드 백신 공동 개발
차바이오텍의 자회사 마티카 바이오테크놀로지가 백스돔과의 협력으로 항바이러스 하이브리드 백신 개발에 성공, 긍정적인 기술 파트너십으로 주가 상승 기대.

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 8,960Won52-week high 23,85052-week low 8,550

1-month return0.0Point

1m -21.27% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

7 totalPositive 1Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-03
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-01
Neutral타인에대한담보제공결정2026-06-26
Neutral[기재정정]타법인주식및출자증권취득결정2026-06-26
Positive유상증자결정(종속회사의주요경영사항)2026-06-26